Henk J Adriaansen

Henk J Adriaansen

Auto-generated profile, based on publicly available information

Henk J Adriaansen

Clinical Chemistry and Hematology Laboratory, Gelre Hospitals , P.O. Box 9014, 7300 DS Apeldoorn

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
CACarlijn M van der Aalst
Carlijn M van der Aalst
SDSabine J A M Denissen
Sabine J A M Denissen
MVMarleen Vonder
Marleen Vonder
JGJan Willem C Gratama
Jan Willem C Gratama
HAHenk J Adriaansen
Henk J Adriaansen
HKHarry J de Koning
Harry J de Koning
Aims: Screening for a high cardiovascular disease (CVD) risk followed by preventive treatment can potentially reduce coronary heart disease-related morbidity and mortality. ROBINSCA (Risk Or Benefit IN Screening for CArdiovascular disease) is a population-based randomized controlled screening trial that investigates the effectiveness of CVD screening in asymptomatic participants using the Systematic COronary Risk Evaluation (SCORE) model or coronary artery calcium (CAC) scoring. This study describes the distributions in risk and treatment in the ROBINSCA trial. Methods and results: Individuals at expected elevated CVD risk were randomized into screening arm A (n = 14 478; SCORE, 10-year fatal and non-fatal risk); or screening arm B (n = 14 450; CAC scoring). Preventive treatment was largely advised according to current Dutch guidelines. Risk and treatment differences between the screening arms were analysed. A total of 12 185 participants (84.2%) in arm A and 12 950 (89.6%) in arm B were screened. In total, 48.7% were women, and median age was 62 (interquartile range 10) years. SCORE screening identified 45.1% at low risk (SCORE < 10%), 26.5% at intermediate risk (SCORE 10–20%), and 28.4% at high risk (SCORE ≥ 20%). According to CAC screening, 76.0% were at low risk (Agatston < 100), 15.1% at high risk (Agatston 100–399), and 8.9% at very high risk (Agatston ≥ 400). CAC scoring significantly reduced the number of individuals indicated for preventive treatment compared to SCORE (relative reduction women: 37.2%; men: 28.8%). Conclusion: We showed that compared to risk stratification based on SCORE, CAC scoring classified significantly fewer men and women at increased risk, and less preventive treatment was indicated. Trial registration number: NTR6471.

31 August 2024 in European Heart Journal Open
Verified
Journal Article
Open access
PDF file
DMDana Moldovanu
Dana Moldovanu
HKHarry de Koning
Harry de Koning
MVMarleen Vonder
Marleen Vonder
JGJan Willem C Gratama
Jan Willem C Gratama
HAHenk J Adriaansen
Henk J Adriaansen
CACarlijn M van der Aalst
Carlijn M van der Aalst
Evidence on the impact of screening for cardiovascular diseases (CVDs) on health-related quality of life (HRQoL) is important for policy decisions about screening implementation and to uncover teachable moments to motivate healthy lifestyle choices. It is unknown whether screening by cardiac computed tomography (CT) scan has a stronger impact on HRQoL than screening by traditional risk prediction models. The study aims to investigate differences in HRQoL across the screening process between participants who were randomized to CVD risk estimation by coronary artery calcium score or Systematic COronary Risk Evaluation. A subset of 2687 ROBINSCA participants filled in questionnaires at (T0) randomization, (T1) invitation, (T2) 1–3 days before screening, (T3) 1–3 days after, and (T4) screening result. Generic HRQoL (SF-12; EQ-5D) and anxiety (STAI-6) were measured. We investigated the differences in changes in HRQoL across the screening process with linear mixed models. We found comparable levels of HRQoL at all screening moments for the two intervention groups. Mental health scores were worse at invitation and randomization than at the later time points, irrespective of screening group (all P < 0.001). A result indicating a heightened CVD risk was associated with increased anxiety in the CT screening group. Computed tomography screening for CVD risk has no detrimental impact on HRQoL and anxiety levels compared to screening by traditional risk assessment. Receiving an invitation to screenning or a result implying increased CVD risk could function as teachable moments for high-risk individuals. ROBINSCA trial registration number: NTR6471 in Dutch Trial Register (NTR). Heart problems make up about a third of all deaths around the world. Detecting and treating heart issues early in people who are at high risk but do not show symptoms could help prevent serious health problems and death. This study is part of a bigger trial that was the first of its kind to compare two methods of screening for early signs of heart disease. The more traditionally method predicts how likely one is to develop heart problems based on age, sex, smoking, cholesterol levels, and blood pressure. The second method uses a CT scan to determine the build-up of calcium deposits in the heart’s blood vessels or tissues. This study looked into how these two methods affect the anxiety and quality of life of participants. We did not find any harmful psychological effects from using CT scans for screening, compared to the usual risk calculation methods. Getting invited to a screening and learning about higher heart disease risk after a CT scan could cause some stress, but it is not too worrying. These moments could be good opportunities for motivating people to adopt healthy behaviours.